AR020080A1 - UNA VACUNA PARA LA INMUNIZACIoN TERAPÉUTICA O PROFILÁCTICA CONTRA EL VIRUS ENCEFALITIS EQUINA VENEZOLANA,Y, UNA COMPOSICIoN FARMACÉUTICA - Google Patents

UNA VACUNA PARA LA INMUNIZACIoN TERAPÉUTICA O PROFILÁCTICA CONTRA EL VIRUS ENCEFALITIS EQUINA VENEZOLANA,Y, UNA COMPOSICIoN FARMACÉUTICA

Info

Publication number
AR020080A1
AR020080A1 ARP990102534A ARP990102534A AR020080A1 AR 020080 A1 AR020080 A1 AR 020080A1 AR P990102534 A ARP990102534 A AR P990102534A AR P990102534 A ARP990102534 A AR P990102534A AR 020080 A1 AR020080 A1 AR 020080A1
Authority
AR
Argentina
Prior art keywords
vaccine
equine encephalitis
venezuelan equine
encephalitis virus
vee
Prior art date
Application number
ARP990102534A
Other languages
English (en)
Original Assignee
Secr Defence
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Secr Defence filed Critical Secr Defence
Publication of AR020080A1 publication Critical patent/AR020080A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se describe una vacuna para la inmunizacion terapéutica o profiláctica para uso en la proteccion de mamíferos, como por ejemplo, humanos o animales contrael virus Encefalitis Equina Venenzolana (VEE). En particular, la vacuna comprende un virus recombinante, tal como un virus vaccinia recombinante que sea capazde expresar los genes estructurales del VEE en forma atenuada, que se ha modificado para aumentar el efecto protector de la vacuna. Estos se logra pormodificacion de la secuencia de la cepa del VEE atenuada y/o poniendo esto bajo control de promotor modificado, lo cual aumenta la expresion del vector. Ademásse describen una composicion farmacéutica de la vacuna, así como también una vacuna multivalente y el uso de un vector que incluye una secuencia que codificauna forma atenuada del virus de Encefalitis Equina Venezolana (VEE) para la manufactura de un medicamento.
ARP990102534A 1998-05-29 1999-05-28 UNA VACUNA PARA LA INMUNIZACIoN TERAPÉUTICA O PROFILÁCTICA CONTRA EL VIRUS ENCEFALITIS EQUINA VENEZOLANA,Y, UNA COMPOSICIoN FARMACÉUTICA AR020080A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9811433A GB2337755B (en) 1998-05-29 1998-05-29 Virus vaccine

Publications (1)

Publication Number Publication Date
AR020080A1 true AR020080A1 (es) 2002-04-10

Family

ID=10832820

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990102534A AR020080A1 (es) 1998-05-29 1999-05-28 UNA VACUNA PARA LA INMUNIZACIoN TERAPÉUTICA O PROFILÁCTICA CONTRA EL VIRUS ENCEFALITIS EQUINA VENEZOLANA,Y, UNA COMPOSICIoN FARMACÉUTICA

Country Status (14)

Country Link
US (2) USRE41745E1 (es)
EP (1) EP1084261B8 (es)
AR (1) AR020080A1 (es)
AT (1) ATE275631T1 (es)
AU (1) AU3834999A (es)
BR (1) BR9910814A (es)
CA (1) CA2329133C (es)
DE (1) DE69920011T2 (es)
DK (1) DK1084261T3 (es)
ES (1) ES2224655T3 (es)
GB (1) GB2337755B (es)
MX (1) MXPA00011708A (es)
PT (1) PT1084261E (es)
WO (1) WO1999063098A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2337755B (en) 1998-05-29 2003-10-29 Secr Defence Virus vaccine
US8623379B2 (en) 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
EP2388015A1 (en) 2000-03-02 2011-11-23 Emory University DNA expression vectors and methods of use
JP4554887B2 (ja) * 2001-03-08 2010-09-29 アメリカ合衆国 改変ＨＩＶエンベロープ、ｇａｇ、およびｐｏｌ遺伝子を発現するＭＶＡ
EP1528677B1 (en) * 2003-10-30 2006-05-10 Agilent Technologies, Inc. Film acoustically-coupled transformer with two reverse c-axis piezoelectric elements
RU2275937C1 (ru) * 2004-10-19 2006-05-10 Вирусологический центр НИИ Микробиологии Министерства обороны Российской Федерации Способ презентации вирусных антигенов иммунной системе хозяина, основанный на протеасомоопосредованной технологии, предназначенный для разработки методов биологической защиты
WO2008101349A1 (en) * 2007-02-23 2008-08-28 Her Majesty The Queen, In Right Of Canada, As Repesented By The Minister Of National Defence Recombinant viral vectors for prevention and protection against alphavirus infection
EP2440251A4 (en) 2009-06-09 2013-01-16 Defyrus Inc INTERFERON ADMINISTRATION FOR PROPHYLAXIS AGAINST PATHOGEN INFECTION OR TREATMENT OF PATHOGEN INFECTION
WO2012112691A1 (en) 2011-02-15 2012-08-23 Immune Design Corp. Methods for enhancing immunogen specific immune responses by vectored vaccines
EA027236B1 (ru) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
WO2013151567A1 (en) * 2012-04-04 2013-10-10 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of U.S. Army Medical Research Institute Of Infectious Diseases Equine encephalitis virus vaccines and methods of using thereof
HRP20181102T1 (hr) 2012-05-16 2018-09-07 Immune Design Corp Cjepiva za hsv-2
MX377561B (es) * 2012-11-05 2025-03-10 Regeneron Pharma Animales no humanos genéticamente modificados y métodos de uso de los mismos.
ES2738582T3 (es) 2014-02-14 2020-01-23 Immune Design Corp Inmunoterapia del cáncer a través de combinación de inmunoestimulación local y sistémica
KR20170032373A (ko) 2014-07-15 2017-03-22 이뮨 디자인 코포레이션 Tlr4 작용제 보조제 및 렌티바이러스 벡터를 이용한 프라임-부스트 요법
ES2921605T3 (es) 2016-01-29 2022-08-30 Bavarian Nordic As Vacuna contra el virus de la encefalitis equina basada en el virus de la variolovacuna modificado Ankara (VMA) recombinante
MX2018012472A (es) 2016-04-15 2019-08-12 Alpine Immune Sciences Inc Proteinas inmunomoduladoras variantes de ligando icos y sus usos.
WO2017181152A2 (en) 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
WO2018022946A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
KR20190141146A (ko) 2017-03-16 2019-12-23 알파인 이뮨 사이언시즈, 인코포레이티드 Pd-l2 변이체 면역조절 단백질 및 그의 용도
SG11201907769XA (en) 2017-03-16 2019-09-27 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
EP3596116B1 (en) 2017-03-16 2023-09-06 Alpine Immune Sciences, Inc. Pd-l1 variant immunomodulatory proteins and uses thereof
KR20260047644A (ko) 2017-03-30 2026-04-08 더 유니버서티 어브 퀸슬랜드 키메라 분자 및 그의 용도
EP3687561A4 (en) 2017-09-01 2021-06-09 The Australian National University "immunoregulatory molecules and uses therefor"
JP7749319B2 (ja) 2017-10-10 2025-10-06 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用
BR112020007542A2 (pt) 2017-10-18 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras ligantes de icos variantes e composições e métodos relacionados
AU2019205273B2 (en) 2018-01-03 2024-04-04 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
EP3853247A2 (en) 2018-09-19 2021-07-28 Alpine Immune Sciences, Inc. Methods and uses of variant cd80 fusion proteins and related constructs
CA3120868A1 (en) 2018-11-30 2020-06-04 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
MX2021012607A (es) 2019-04-17 2022-03-11 Alpine Immune Sciences Inc Metodos y usos de proteinas de fusion de ligando icos (icosl) variante.
EP4146684A2 (en) 2020-05-08 2023-03-15 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof
US20240279310A1 (en) 2021-05-07 2024-08-22 Alpine Immune Sciences, Inc. Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
WO2023172883A1 (en) 2022-03-07 2023-09-14 Alpine Immune Sciences, Inc. Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
KR20250099778A (ko) 2022-10-04 2025-07-02 알파인 이뮨 사이언시즈, 인코포레이티드 자가항체-매개 질환의 치료에 사용하기 위한 돌연변이된 taci-fc 융합 단백질

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185440A (en) * 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
US5505947A (en) * 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US6261570B1 (en) * 1997-05-20 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants
GB2337755B (en) 1998-05-29 2003-10-29 Secr Defence Virus vaccine

Also Published As

Publication number Publication date
AU3834999A (en) 1999-12-20
WO1999063098A1 (en) 1999-12-09
EP1084261B8 (en) 2004-12-15
ES2224655T3 (es) 2005-03-01
CA2329133C (en) 2011-07-12
GB9811433D0 (en) 1998-07-22
GB2337755B (en) 2003-10-29
GB2337755A (en) 1999-12-01
EP1084261B1 (en) 2004-09-08
DE69920011T2 (de) 2005-09-15
MXPA00011708A (es) 2005-10-13
EP1084261A1 (en) 2001-03-21
CA2329133A1 (en) 1999-12-09
PT1084261E (pt) 2005-01-31
BR9910814A (pt) 2001-02-13
DK1084261T3 (da) 2005-01-17
ATE275631T1 (de) 2004-09-15
DE69920011D1 (de) 2004-10-14
US6936257B1 (en) 2005-08-30
USRE41745E1 (en) 2010-09-21

Similar Documents

Publication Publication Date Title
AR020080A1 (es) UNA VACUNA PARA LA INMUNIZACIoN TERAPÉUTICA O PROFILÁCTICA CONTRA EL VIRUS ENCEFALITIS EQUINA VENEZOLANA,Y, UNA COMPOSICIoN FARMACÉUTICA
MX2019012101A (es) Vacuna contra vhb.
CL2018003769A1 (es) Una cepa del virus atenuado de la peste porcina africana desarrollada racionalmente que, protege contra la infección por el virus parental georgia 2007 aislado.
CL2018000587A1 (es) Adenovirus oncolítico que codifica una proteína b7 (divisional de sol. n° 2731-2017)
BR9912410A (pt) Vacina para imunização de aves, e, processos para imunizar uma ave e para preparar uma vacina para imunizar uma ave
EP4104854A3 (en) Multivalent vaccines for rabies virus and coronaviruses
CO2020002283A2 (es) Métodos de terapia génica del factor viii (fviii)
ITMI20021527A1 (it) Anticorpi anti componente c5 del complemento e loro uso
AR110502A1 (es) Polinucleótidos y polipéptidos de adenovirus
AR105482A1 (es) Vectores virales recombinantes que contienen la proteína menor del virus del síndrome reproductor y respiratorio porcino (prrsv) y sus métodos de elaboración y uso
CO5700788A2 (es) Composiciones y metodos para inmunoterapia especifica de wt1
ZA202204373B (en) Development of a novel live attenuated african swine fever vaccine based in the deletion of gene i177l
ES2157964T3 (es) Procedimiento de estabilizacion de vesiculas de lipido(s) anfifilo(s) y composicion para aplicacion topica que contiene dichas vesiculas estabilizadas.
AR100419A1 (es) Vectores de virus adenoasociados para el tratamiento de trastornos de almacenamiento lisosómico
CL2022002416A1 (es) Vacuna
ES2676542T3 (es) Composiciones de CDV recombinante y usos de las mismas
BRPI0416916A (pt) promotores para expressão em vìrus de vacìnia modificada ankara
ES2117029T3 (es) Vacuna contra la coccidiosis aviar.
CO2023017148A2 (es) Composiciones de suministro de terapia génica y métodos para tratar perdida auditiva
AR062979A1 (es) Formulaciones orales liofilizadas de desintegracion rapida de un antagonista del receptor de trombina
CO2020013690A2 (es) Composiciones y métodos para el tratamiento de la distrofia macular
MX2022003069A (es) Agente para inducir inmunidad especifica contra el virus del sindrome respiratorio agudo grave sars-cov-2 en forma liquida (variantes).
ES2192559T3 (es) Vacuna para la proteccion de aves de corral contra la coccidiosis.
CL2020001494A1 (es) Uso de una proteína no estructural de prv para proteger contra la inflamación del músculo esquelético y cardíaco.
PH12022550063A1 (en) Vaccine

Legal Events

Date Code Title Description
FG Grant, registration